SMTL ID : 6mx8.1

Crystal structure of anaplastic lymphoma kinase (ALK) bound by Brigatinib

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 1.96 Å

Oligo State

monomer

Ligands

1 x 6GY: 5-chloro-N~4~-[2-(dimethylphosphoryl)phenyl]-N~2~-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine(Non-covalent)

6GY.1: 14 residues within 4Å: Chain A: L.29, H.31, V.37, A.55, L.103, E.104, L.105, M.106, A.107, G.109, E.117, R.160, L.163, D.177 5 PLIP interactions: 5 interactions with chain A Hydrophobic interactions: A:L.29 Hydrogen bonds: A:M.106, A:M.106 Salt bridges: A:E.117, A:E.117

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Huang, W.S. et al., Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase. J. Med. Chem. (2016)

Release Date

2018-12-12

Peptides

ALK tyrosine kinase receptor: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

ALK tyrosine kinase receptor